VBI craters as investors react to Hep B vaccine dataVBI Vaccines has trumpeted top-line data from a trial pitting its hepatitis B virus (HBV) vaccine candidate against Share XVBI craters as investors react to Hep B vaccine datahttps://pharmaphorum.com/news/vbi-craters-as-investors-react-to-hep-b-vaccine-data/
bluebird offers instalment payments for Zynteglo gene therapybluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with Share Xbluebird offers instalment payments for Zynteglo gene therapyhttps://pharmaphorum.com/news/bluebird-offers-instalment-payments-for-zynteglo-gene-therapy/
Lilly’s Taltz scrapes win against Humira in psoriatic arthritisEli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been Share XLilly’s Taltz scrapes win against Humira in psoriatic arthritishttps://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/
GSK makes CRISPR play, funding Doudna lab in CaliforniaGlaxoSmithKline has forged an alliance with two leading CRISPR researchers that will see the creation of a new Share XGSK makes CRISPR play, funding Doudna lab in Californiahttps://pharmaphorum.com/news/gsk-makes-crispr-play-funding-doudna-lab-in-california/
Sobi cuts staff and buys Novimmune drug in refocusSobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst Share XSobi cuts staff and buys Novimmune drug in refocushttps://pharmaphorum.com/news/sobi-cuts-staff-novimmune-drug-refocus/
Novo Nordisk builds cardio claim case for oral semaglutideNovo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has Share XNovo Nordisk builds cardio claim case for oral semaglutidehttps://pharmaphorum.com/news/novo-nordisk-builds-cardio-claim-case-for-oral-semaglutide/
Insys throws in the towel and files for bankruptcyInsys has declared bankruptcy, hard on the heels of its agreement last week to a $225 million payment Share XInsys throws in the towel and files for bankruptcyhttps://pharmaphorum.com/news/insys-throws-in-the-towel-and-files-for-bankruptcy/
Merck bolts on another immunology firm with $773m Tilos dealMerck & Co/MSD has agreed to buy privately held biotech Tilos Therapeutics for up to $773 million, its Share XMerck bolts on another immunology firm with $773m Tilos dealhttps://pharmaphorum.com/news/merck-bolts-on-another-immunology-firm-with-773m-tilos-deal/
Sanofi, Lilly and Novo make cases for diabetes drugs at ADAThe American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and Share XSanofi, Lilly and Novo make cases for diabetes drugs at ADAhttps://pharmaphorum.com/news/sanofi-lilly-and-novo-diabetes/
